

## Microsatellite Instability

Genomic instability is broadly classified into microsatellite instability associated with mutator phenotype and chromosome instability recognized by gross chromosomal abnormalities. A defect in DNA mismatch repair (MMR) is responsible for hereditary nonpolyposis colorectal carcinoma (HNPCC). Target genes for microsatellite instability (MSI) include *TGFBRII*, *IGFIIR*, *BAX*, *hMSH3*, *hMSH6*, and *MBD4* [4]. MSI or genetic instability causes accumulation of genetic alterations and participates in pathogenesis of sporadic gastric carcinomas as well [4]. The frequency of MSI is estimated to be about 30% of gastric carcinoma; the frequency is especially high in well-differentiated gastric carcinoma of foveolar phenotype with papillary morphology. Some intestinal metaplasias and adenomas also show MSI, and these should be considered "true precancerous lesions." Another important aspect of genetic instability is that multiple primary cancers frequently display MSI. Representative reports demonstrating the relation between MSI and tumor multiplicity are shown in Table 2. Although the frequency of MSI differs depending on the number and site of microsatellites, all show that the frequency of MSI is significantly higher in cases with multiple primary cancers. This finding indicates that the detection of MSI in a cancer may serve as a good molecular marker for the assessment of the risk of a second cancer in the same patient. CpG island hypermethylation of *hMLH1* and loss of expression is the main mechanism of MSI in sporadic gastric carcinoma [15].

## Cell-Cycle Regulators

Cell-cycle checkpoints are regulatory pathway that control cell-cycle transitions and ensure that DNA replication and chromosome segregation are completed with high fidelity. The checkpoints also respond to damage by arresting the cell cycle to provide time for repair. Imbalance in cell-cycle regulators results in genomic instability and unbridled cell proliferation and is implicated in stomach carcinogenesis [2,4]. Table 3 shows representative abnormalities of cell-cycle regulators found in gastric carcinoma. The cyclin E gene is amplified in 15%–20% of gastric carcinoma, and the over-

TABLE 2. Representative reports of Microsatellite instability (MSI) and multiple primary gastric carcinomas

Multiple vs. solitary		MSI cases	Reference
Early gastric cancer	Multiple cancer	21/63 (33%)	Takahashi H, Endo T, Yamashita K, et al. (2002) Int J Cancer 100:419–424
	Solitary cancer	3/39 (8%)	
Synchronous gastric cancer + adenoma	Multiple cancer	9/18 (50%)	Lee HS, Lee BL, Woo DK, et al. (2001) Int J Cancer 91:619–624
	Solitary cancer	14/149 (9%)	
Gastric cancer	Multiple cancer	11/14 (79%)	Nakashima H, Honda M, Inoue H, et al. (1995) Int J Cancer 64:239–242
	Solitary cancer	5/24 (21%)	
Gastrointestinal and biliary cancer	Multiple cancer	34/38 (89%)	Horii A, Han JHJ, Shimada M, et al. (1994) Cancer Res 54:3373–3375
	Solitary cancer	19/174 (11%)	

TABLE 3. Abnormalities in cell-cycle regulators found in gastric carcinoma

Cell-cycle regulators	Method <sup>a</sup>	Incidence	Role <sup>b</sup>	References
CDC2 high kinase activity	Kinase	92%	D	Yasui W, Ayhan A, Kitadai Y et al. (1993) <i>Int J Cancer</i> 53:36–41
Cyclin E gene amplification	Southern	16%	P	Akama Y, Yasui W, Yokozaki H, et al. (1995) <i>Jpn J Cancer Res</i> 86:617–621
Cyclin E overexpression	IHC	27%	D/P	Yasui W, Yokozaki H, Shimamoto F, et al. (1999) <i>Pathol Int</i> 49:763–774
CDC25A overexpression	Northern	38%	D	Kudo Y, Yasui W, Ue T, et al. (1997) <i>Jpn J Cancer Res</i> 88:947–952
CDC25B overexpression	Northern	70%	D/P	Kudo Y, Yasui W, Ue T, et al. (1997) <i>Jpn J Cancer Res</i> 88:947–952
p21 reduced expression	Northern	53%	D	Akama Y, Yasui W, Kuniyasu H, et al. (1996) <i>Mol Cell Differ</i> 4:187–198
p21 reduced expression	IHC	46%	D	Yasui W, Akama Y, Kuniyasu H, et al. (1996) <i>J Pathol</i> 180:122–128
p27 reduced expression	IHC	56%	D/P	Yasui W, Kudo Y, Semba S, et al. (1997) <i>Jpn J Cancer Res</i> 88:625–629
E2F-1 overexpression	Northern	40%	D	Suzuki T, Yasui W, Yokozaki H, et al. (1999) <i>Int J Cancer</i> 81:535–538
E2F-3 reduced expression	Northern	70%	D	Suzuki T, Yasui W, Yokozaki H, et al. (1999) <i>Int J Cancer</i> 81:535–538
Chk1 overexpression	Western	71%	D	Shigeishi H, Yokozaki H, Oue N, et al. (2002) <i>Int J Cancer</i> 99:58–62
Chk2 overexpression	Western	78%	D	Shigeishi H, Yokozaki H, Oue N, et al. (2002) <i>Int J Cancer</i> 99:58–62

<sup>a</sup> Kinase, kinase assay; Southern, Southern blotting; Northern, Northern blotting; IHC, immunohistochemistry; Western, Western blotting

<sup>b</sup> Participation in tumor development (D) or progression (P)

expression of cyclin E tends to correlate with tumor invasion and advanced stage. The overexpression of CDC25B is found in 70% of gastric carcinoma that is associated with invasion and metastasis. On the other hand, reduction in the expression of p27<sup>Kip1</sup> is associated with both development and progression of gastric carcinoma. An important downstream target of cyclins/CDKs at G<sub>1</sub>/S transition is a family of transcription factor E2F. E2F-1 is overexpressed in 40% of gastric carcinoma and 70% of gastric carcinomas show reduced expression of E2F-3, suggesting that E2F family members may have a distinct role in stomach carcinogenesis. Chk1 and Chk2 are DNA damage-activated kinases involved in the G<sub>2</sub>/M checkpoint. Both Chk1 and Chk2 are overex-

pressed in more than 70% of gastric carcinoma. The overexpression is associated with *p53* mutations. Therefore, Chk1 and Chk2 may play a role in checkpoint function in gastric carcinoma harboring *p53* mutation when their functions are preserved to prevent cell-cycle progression.

## Angiogenic Factors

Angiogenesis, which is a prerequisite for tumor growth and metastasis, depends on the production of angiogenic factors by host and tumor cells (Fig. 2). Increased vascularity enhances the growth of primary neoplasms and provides an avenue for hematogenous metastasis. In gastric carcinoma, increasing microvessel counts correlate with lymph node metastasis, hepatic metastasis, and poor prognosis. Several growth factors have been identified that regulate angiogenesis in gastric carcinoma [4]. Gastric carcinoma cells produce various angiogenic factors, including vascular endothelial growth factor (VEGF), interleukin (IL)-8, basic fibroblast growth factor (bFGF), and platelet-derived endothelial cell growth factor (PD-ECGF) [4,16–18]. Takahashi et al. [16] have found that the angiogenic phenotype differs between the well-differentiated type and poorly differentiated type of gastric carcinoma. Well-differentiated-type tumors, but not the poorly differentiated type, highly express VEGF, whose levels significantly correlate with vessel counts. bFGF expression was higher in the poorly differentiated type, especially scirrhous-type carcinoma. A majority of gastric carcinomas express IL-8/receptor systems, and the expression levels of IL-8 directly correlate with tumor vascularity [17]. Gastric carcinoma cells transfected with the IL-8 gene produce rapidly growing and highly vascular neoplasms at the orthotopic site (gastric wall) in nude mice [19]. Furthermore, IL-8 increases the expression of EGFR, VEGF, and IL-8 itself by the tumor cells themselves [20].

The microenvironment may influence the angiogenic phenotype of gastric carcinoma. In our *in vitro* study, *H. pylori* infection, a candidate promoter for gastric carcinoma, increased expression of mRNA encoding IL-8, VEGF, and angiogenin by tumor cells [21]. In addition to the neoplastic cells, various interstitial cells in the tumor microenvironment may be involved in angiogenesis. Macrophage infiltration into gastric carcinoma correlates significantly with tumor vascularity and monocyte chemoattractant protein (MCP)-1 expression by tumor cells. Because the activated macrophage is a producer for VEGF, IL-8, and PD-ECGF, MCP-1 expressed by gastric carcinoma cells plays a role in angiogenesis via macrophage recruitment and activation.

## Molecular Bases of Gastric and Intestinal Phenotype

### Gastric Carcinoma

Well-differentiated gastric carcinoma is classified into those with gastric and intestinal phenotypes by mucin histochemistry and immunohistochemistry [22]. Gastric carcinoma cells can be differentiated into a gastric epithelial cell (G) type, resembling pyloric glands and foveolar epithelia, and an intestinal epithelial cell (I) type, such as goblet and intestinal absorptive cells, by analyzing phenotypic expression. The *p53* gene abnormalities are frequently associated with I-type carcinoma, whereas LOH of the *p73* gene, a homologue of *p53*, occurs specifically in G type with foveolar epithe-

lial phenotype [23,24]. Caudal-type homeobox (*CDX*) 1 and *CDX2* are members of the caudal-related homeobox gene family, and *CDX* proteins act as intestine-specific transcription factors [25]. *CDX2* upregulates goblet-specific *MUC2* gene expression [26]. I-type carcinomas express *CDX1* and *CDX2* at high levels [25]. Liver-intestine (LI) cadherin, also known as cadherin 17 (*CDH17*), is overexpressed in I-type carcinoma that is correlated with tumor invasion and metastasis [27–29]. It has been shown that *CDX2* binds to the promoter of *CDH17* and upregulates gene expression [30]. On the other hand, the expression of *SOX2*, a member of transcription factor family containing an *Sry*-like high-mobility group box, is well preserved in G-type carcinoma and down-regulated in I-type carcinoma [22]. MSI associated with *hMLH1* hypermethylation is frequent in G-type carcinoma [23]. Details of the molecular bases of gastric carcinoma with foveolar epithelial phenotype are described in chapter by Yokozaki et al. (this volume).

## Epigenetic Alterations of Tumor-Related Genes

### *DNA Methylation*

Many lines of evidence indicate that DNA methylation is important in differential control of gene expression. The abnormal methylation of CpG islands associated with tumor suppressor genes can lead to transcriptional silencing, inactivating the gene and participating in tumorigenesis. In gastric carcinoma, aberrant methylation is involved in the inactivation of various important genes such as *p16<sup>MTS1/INK4A</sup>*, *CDH1* (E-cadherin), *hMLH1*, *RAR-beta*, *RUNX3*, *MGMT* (*O*<sup>6</sup>-methylguanine methyltransferase), *TSP1* (thrombospondin-1), *HLTF* (helicase-like transcription factor), *RIZ1* (retinoblastoma protein-interacting zinc finger gene-1), and *CHFR* [4,31–36]. The incidence of DNA hypermethylation and inactivation of these genes in gastric carcinoma ranges from 10% to 70%. The expression is restored by treatment of 5-aza-2'-deoxytydine (5-aza-dC), a DNA methyltransferase inhibitor. Because these genes have respective functions, the inactivation participates in stomach carcinogenesis through abnormalities in cell-cycle regulation, cell adhesion property, signal transduction, gene regulation, DNA repair, and so on. Carcinomas frequently have the CpG island methylator phenotype (CIMP) [37]. Gastric carcinomas showing methylation at more than three of the five loci of *methylated in tumors* (MINT) were designated as CIMP positive. Significant association is found between the CIMP-positive and promoter hypermethylation of *hMLH1*, *p16*, *CDH1*, and *RAR-beta*. By a genome scanning technique, methylation-sensitive representational difference analysis, Kaneda et al. [38] found that nine CpG islands (CGIs) in the 5'-regions of nine genes, *LOX*, *HRASLS*, *bA305P22.2.3*, *FLNc* (gamma-filamin/ABPL), *HAND1*, a homologue of *RIKEN 2210016F16*, *FLJ32130*, *PGAR* (*HFARP/ANGPTL4/ARP4*), and thrombomodulin, were methylated in gastric carcinoma cell lines but unmethylated in the normal samples. These genes may include important genes in gastric carcinoma development and would be useful to identify a distinct subset of gastric carcinomas.

Alterations in DNA methylation patterns sometimes differ depending on histological type of gastric carcinoma [39,40]. Hypermethylation of *hMLH1* is frequent in pap-

illary subtype (foveolar phenotype) of well-differentiated adenocarcinomas [23]. On the other hand, CpG island methylation of *CDH-1* and reduced E-cadherin expression is commonly observed in poorly differentiated adenocarcinoma of nonsolid (scirrhous) type [39]. Methylation of *CDH1* promoter is known as the second genetic hit in hereditary scirrhous gastric carcinoma. Furthermore, CIMP and *p16* methylation are frequent in well-differentiated type or poorly differentiated solid type, whereas *RAR-beta* methylation is common in the poorly differentiated nonsolid type [40].

In addition to tumor-specific DNA methylation, some gene promoters become hypermethylated in nonneoplastic condition during aging. Alternatively, the incidence of promoter hypermethylation of *hMLH1* and *p16* is more frequent in nonneoplastic gastric mucosa of gastric carcinoma patients than in those of noncancer individuals. Although hypermethylation of *hMLH1*, *p16*, *TSP1*, and *TIMP-3* sometimes occurs in intestinal metaplasia and adenomas, the number of methylated genes increases from normal mucosa to intestinal metaplasia to adenoma to carcinoma [41]. These observations indicate that DNA methylation occurs early and accumulates along the multistep stomach carcinogenesis.

Although DNA methyltransferase and demethylase are enzymes potentially affecting promoter methylation status, tumor-specific hypermethylation is not fully understood and does not simply depend on the expression levels of promethylating (DNMT1, DNMT3A, DNMT3B) and antimethylating (MBD2) enzymes. It has been shown that DNMT1 and DNMT3B cooperate to silence genes and that DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancers [42,43].

### *Histone Modification and Chromatin Remodeling*

Histone acetylation and chromatin remodeling linked with CpG island methylation play a major role in the epigenetic regulation of gene expression [44]. Acetylation of histones through an imbalance of histone acetyltransferases and deacetylases disrupts nucleosome structure, which leads to DNA relaxation and a subsequent increase in accessibility for transcription factors. There is a tight association between histone acetylation and DNA methylation. Histone deacetylase-1 (HDAC1) can form a complex with both methyl-CpG-binding proteins (MeCP) and DNMT1 to silence the gene expression. In contrast, methylation of histone tails is alternately linked to activation and repression, depending on the residue methylated [45]. The expression of acetylated histone H4 is reduced in 70% of gastric carcinomas, 40% of gastric adenomas, and some of the intestinal metaplasia adjacent to carcinoma, suggesting that a low level of global histone acetylation may occur even in precancerous cells [5]. Furthermore, reduced histone acetylation is significantly associated with depth of tumor invasion and nodal metastasis of gastric carcinoma. Hypoacetylation of histones H3 and H4 in the *p21<sup>WAF1/Cip1</sup>* promoter region is observed in more than 50% of gastric cancer tissues by chromatin immunoprecipitation (ChIP). Hypoacetylation of histone H3 in the promoter is associated with reduced expression of p21 regardless of *p53* gene status. A HDAC inhibitor, trichostatin A (TSA), induces growth arrest and apoptosis and suppresses invasion of gastric carcinoma cells [5]. TSA increases the expression of p21, CBP, Bak, and cyclin E, while it reduces the

expression of E2F-1, E2F-4, HDAC-1, and the phosphorylated form of Rb protein [5]. TSA also induces the expression of many suppressor genes of invasion and metastasis including TIMPs and nm23H1/H2. These findings suggest that histone deacetylation may participate not only in tumorigenesis but also in invasion and metastasis through modifying a variety of gene expression. Therefore, histone acetylation should be a promising target for cancer therapy, especially against invasive and metastatic disease.

Histone hypoacetylation and DNA hypermethylation occur concordantly in transcriptional regulation of several genes. For instance, HLTF is a homologue to SWI/SNFs, which are ATP-dependent chromatin remodeling enzymes [34]. Half of gastric cancers show DNA methylation of *HLTF* gene, whereas no gastric mucosa from healthy subjects show the methylation. Loss of HLTF expression in gastric carcinoma cells is rectified by 5-aza-dC and TSA. The acetylation levels of histones H3 and H4 in the CpG island of the *HLTF* are inversely associated with DNA methylation status.

## Genetic Polymorphism and Gastric Carcinoma Risk

Genetic polymorphism is an important determinant for the endogenous cause of cancer. Individual variations in cancer risk are associated with genetic polymorphisms (specific variant alleles of different genes) that are present in a significant proportion of the normal population. Gonzalez et al. [46] has described an overview of genetic susceptibility and gastric carcinoma risk. Genetic susceptibility must be crucial in various processes relevant to stomach carcinogenesis, including (1) mucosal protection against *H. pylori* infection or other carcinogens; (2) the inflammatory response that conditions the maintenance, severity, and outcome of the *H. pylori* infection; (3) the functioning of carcinogen detoxification and antioxidant protection; (4) the intrinsic variability of DNA repair processes; and (5) cell proliferation activity. Representative reports of the association between genetic polymorphism and gastric carcinoma risk are shown in Table 4. IL-1beta gene (*IL1B*) and the IL-1 receptor antagonist gene (*IL1RN*) variants *IL1B* (-31 T genotype) and *IL1RN* IVS 86bp VNTR (2/2 genotype), thought to increase IL-1beta production and to inhibit gastric acid secretion, are associated with an increased risk of chronic hypochlorhydric response to *H. pylori* infection and an increased gastric carcinoma risk. *NAT1* is responsible for *N*-acetyltransferase activity, which catalyzes acetylation and modification of aromatic and heterocyclic amine carcinogens. A significant increase of gastric carcinoma risk is associated with genotypes of *NAT1* (1088 T > A, 1095 C > A). In the Japanese population, gastric cancer risk is particularly high in well-differentiated carcinoma and in heavy smokers, suggesting the involvement of *NAT1* in smoking-induced stomach carcinogenesis.

As to the relation between polymorphism of tumor-related genes and cancer risk, several studies have been performed. Single nucleotide polymorphism (SNP) (A > G, Ile > Val) is present in the transmembrane domain of the *HER-2/c-erbB2*. Our case-control study has demonstrated that the Val genotype is significantly more frequent in gastric carcinoma patients than in controls. In patients, gastric carcinomas of advanced stage are more frequent in patients with Val genotype than those with Ile

TABLE 4. Association of genetic polymorphism with gastric carcinoma risk and progression

Gene and molecule	Site of single nucleotide polymorphism (SNP)	Role	Reference
<i>MUC1</i>	Coding VNTR	Risk Portuguese	Carvalho F, Seruca R, David L, et al. (1997) <i>Glycoconj J</i> 14:107-111
Interleukin 1 beta ( <i>IL1B</i> )	Promoter -31 C/T	Risk	El-Omar EM, Carrington M, Chow WH, et al. (2000) <i>Nature (Lond)</i> 404:398-402
Interleukin 1 receptor antagonist ( <i>IL1RN</i> )	IVS2 86-bp VNTR	Risk	El-Omar EM, Carrington M, Chow WH, et al. (2000) <i>Nature (Lond)</i> 404:398-402
<i>N</i> -Acetyltransferase 1 [ <i>NAT1</i> ]	1088 T/A, 1095 C/A	Risk	Kato H, Boissy RJ, Nagata N, et al. (2000) <i>Int J Cancer</i> 85:46-49
Cytochrome P450 2E1 ( <i>CYP2E1</i> )	-1053 C/T	Risk Brazilians	Nishimoto IN, Hanaoka T, Sugimura H, et al. (2000) <i>Cancer Epidemiol Biomark Prev</i> 9:675-680
Glutathione S-transferase P1 ( <i>GSTP1</i> )	Coding Ile105Val	Risk?	Kato H, Kaneko S, Takasawa S, et al. (1999) <i>Pharmacogenetics</i> 9:165-169
Methylenetetrahydrofolate reductase ( <i>MTHFR</i> )	Coding Ala677Val	Risk Chinese	Shen H, Xu Y, Zheng Y, et al. (2001) <i>Int J Cancer</i> 95:332-336
<i>HER-2/c-erbB2</i>	Coding Ile 665 Val	Risk	Kuraoka K, Oue M, Matsumura S, et al. (2003) <i>Int J Cancer</i> 107:593-596
<i>MMP-1</i>	Promoter -1607 G/GG	Histology	Matsumura S, Oue N, Kitadai Y, et al. (2004) <i>J Cancer Res Clin Oncol</i> 130:259-265

genotype, suggesting that this SNP could modulate gastric cancer risk and serve as a predictor of risk for a malignant phenotype. Matrix metalloproteinase-1 (MMP-1) plays a key role in cancer invasion and metastasis. There is 1G/2G SNP in the promoter region of the *MMP-1* affecting the transcriptional activity. Although no difference has been found in the frequency of 1G/2G genotype between gastric carcinoma patients and controls, a significant association is detected with histological differentiation. The 2G genotype is more frequent in poorly differentiated gastric carcinoma than in well-differentiated tumors. Controversial observations have been reported in the association between *CDH1* (E-cadherin) promoter (-160 C > A) polymorphism and the risk of gastric carcinoma. One report indicates that individuals with A/A genotype have a decreased risk of gastric carcinoma [47], whereas another shows no difference in genotype frequencies between gastric carcinoma cases and controls [48]. The important limitations in case-control studies that preclude definitive conclusions are lack of appropriate control, low number of cases analyzed, and lack of concomitant analysis with exposure to relevant cofactors such as *H. pylori* infection and smoking. Proper association studies between genetic polymorphism and cancer risk and genotype information in individuals must be important because those factors directly connect with personalized cancer prevention. Furthermore, genetic polymorphisms have been associated with therapeutic efficacy and toxicity of anticancer drugs [49]. For instance, polymorphism of VNTR in the promoter region of thymidylate synthase influences response to 5-fluorouracil. Polymorphism (difference in number of TA repeats) in the promoter region of the UDP-glucuronosyltransferase 1A1 gene affects severity of toxicity during irinotecan (CPT-11) therapy.

## Novel Genetic Markers Identified by Gene Expression Profile

### *Microarray Study*

Cancer is accompanied by multiple genetic and epigenetic alterations, including mutation, gene amplification, LOH, gene silencing by DNA methylation, and loss of imprinting, all of which modify gene expression profiles. Therefore, genome-wide study of gene expression is greatly important to uncover the precise mechanism of development and progression of cancer. Microarray technology provides high-throughput analysis of gene expression profiles by means of small-array slides. cDNA microarray, array slides spotted with cDNAs, is commonly used to detect differences between tumor and normal cells among various histologies and clinical outcomes, for example. The use of laser capture microdissection and T7-based RNA amplification helps to study gene expression profile in a small amount of sample with minimal contamination of other components than those of interest.

Several microarray studies have been performed on gastric carcinoma. El-Rifai et al. [50] examined the gene expression profile of gastric carcinoma using cDNA microarray with 1200 genes and found that S100A4, CDK4, MMP14, and beta catenin are the most upregulated in gastric carcinoma. Hippo et al. [28] studied the expression profile of 6800 genes and identified 162 that were highly expressed in gastric carcinoma tissues; these included genes related to cell cycle, growth factor, cell motility,



cell adhesion, and matrix remodeling. They also found several genes associated with metastasis, including Oct-2, a POU domain transcription factor, or intestinal histology, including CDH17 and LI-cadherin. Hasegawa et al. [51] performed genome-wide analysis of gene expression in well-differentiated gastric cancer using a cDNA microarray representing 23040 genes and reported that 61 genes and 63 genes were commonly up-regulated and downregulated, respectively, in gastric carcinoma. Altered expression of 12 genes including *DDOST*, *GNS*, *NEDD8*, *LOC51096*, and *AIM2* was found to be associated with lymph node metastasis. Hasegawa et al. developed a “predictive score” based on the expression profiles of these five genes that could distinguish cancers with metastasis from those without metastasis. A similar approach has been carried out by Inoue et al. [52] to develop a prognostic scoring system using cDNA microarray. They selected 78 genes that were differentially expressed between aggressive and nonaggressive groups with respect to conventional pathological parameters and determined a coefficient for each gene. The prognostic score, calculated by summing up the value for each gene, could predict stage of disease and the patient’s prognosis. Those strategies can be applicable to identify genes associated with sensitivity of cancer to anticancer drugs [53]. These observations indicate that the gene expression profile and a scoring system based on microarray analysis have great potential for dissecting the character of gene expression in individual cancers and predicting biological behavior and chemosensitivity.

### *Serial Analysis of Gene Expression (SAGE)*

Besides microarray technique, serial analysis of gene expression (SAGE) is a powerful technique to allow global analysis of gene expression in a quantitative manner without prior knowledge of the sequence of the genes [54]. SAGE is based on the following principles. A short nucleotide sequence tag (about 10 base pairs) is sufficient to uniquely identify a transcript, provided it is isolated from a defined position within the transcript. Concentration of short sequence tags allows the efficient analysis of transcripts in a serial manner by the sequencing of multiple tags within a single clone. Because the SAGE tag numbers directly reflect the abundance of the mRNA, SAGE data are highly accurate and quantitative, and completion of the human genome sequence has facilitated the mapping of specific genes to individual tags. Up to now, four SAGE studies of gastric carcinoma, including ours, have been reported that identified several upregulated and downregulated genes [55–58]. Our SAGE study on five samples of gastric carcinoma of different stages and histology from four patients generated a total of 137706 tags including 38903 unique tags [58]. Our SAGE libraries are the largest gastric carcinoma libraries in the world, and sequence data from our SAGE libraries are publicly available at SAGEmap (GEO accession number GSE 545, SAGE Hiroshima gastric cancer tissue) (<http://www.ncbi.nlm.nih.gov/SAGE/>).

Comparison between SAGE tags from gastric carcinoma and those from normal gastric epithelia identifies upregulated and downregulated genes that may participate in stomach carcinogenesis (Table 5) [29,58]. If SAGE libraries are compared between early cancer and advanced cancer or between primary tumor and metastatic tumor, candidate genes involved in invasion and metastasis can be identified. The upregulated genes in gastric carcinoma include *APOC1*, *NDUF2*, *TEBP*, *COL1A1*, and so on, in addition to *TFF3* and *S100A4*, which are known to be upregulated in gastric carci-

noma [58]. Quantitative real-time reverse transcription-PCR (RT-PCR) confirmed that *APOC1*, *CEACAM6*, and *YF13H12* are frequently overexpressed. The down-regulated gene cluster includes *LIPF* (gastric lipase), *CHIA*, *ATP4B*, *MBD3*, and many unknown genes. By comparing gene expression profiles between gastric carcinomas at early and advanced stages, several differentially expressed genes by tumor stage were also identified, including *FUS*, *CDH17*, *COL1A1*, and *COL1A2*, that should be novel genetic markers for high-grade malignancy. *FUS* is a tumor-associated fusion gene, especially in myxoid liposarcoma, and its possible role is supposed to be to regulate transcription and maintain chromosomal stability [59]. Regarding genes involved in metastasis, the 20 most upregulated tags and corresponding genes in the

TABLE 5. Upregulated and downregulated tags and genes in gastric carcinoma obtained by serial analysis of gene expression (SAGE)

Commonly upregulated and downregulated tags and genes in gastric carcinoma in comparison with normal gastric epithelia	
Upregulated	<i>APOC1</i> , <i>S100A4</i> , <i>NDUF2</i> , <i>TEBP</i> , <i>COL1A2</i> , <i>SUFU</i> , <i>SYAP1</i> , <i>KIAA0930</i> , <i>KIAA1694</i> , <i>TFF3</i> , <i>CEACAM6</i> , <i>FLJ20249</i> , <i>FLJ2167</i> , <i>EIF4A1</i> , <i>COLPH2</i> , <i>G3BP</i> , <i>YF13H12</i> , <i>KRT7</i> , <i>SH3BP2</i> , <i>COL1A1</i> , <i>LOC284371</i>
Downregulated	<i>CAGCGCTTCT</i> (no match), <i>CACCTCCCCA</i> (no match), <i>AGCCTCCCCA</i> (no match), <i>ACCCTCCCCA</i> (no match), <i>LIPF</i> , <i>AACCTCCCCC</i> (no match), <i>CHIA</i> , <i>TAGTGCTTCT</i> (no match), <i>TACAAGGTCC</i> (no match), <i>GTGGTCAGCT</i> (no match), <i>ATP4B</i> , <i>FLJ20410</i> , <i>MBD3</i> , <i>CAGTGCTTTT</i> (no match), <i>Hs.199360</i> , <i>Hs.353061</i>
The 20 most upregulated and downregulated tags and genes in advanced carcinoma in comparison with early carcinoma <sup>a</sup>	
Upregulated	<i>TCCCCGTAAA</i> (no match), <i>TCCCCGTACAT</i> (no match), <i>CDH17</i> , <i>FUS</i> , <i>PRO1073</i> , <i>FLJ36926</i> , <i>FLJ30146</i> , <i>PAI-RBP1</i> , <i>COL1A2</i> , <i>TCCTATTAAG</i> (no match), <i>COL1A1</i> , <i>GRAP2</i> , <i>HNRPL</i> , <i>NUTF2</i> , <i>ERP70</i> , <i>PES1</i> , <i>CYP2J2</i> , <i>DAG1</i> , <i>IQGAP1</i> , <i>IL16</i> , <i>FXYD3</i> , <i>COQ4</i> , <i>LOC91966</i> , <i>CTBP1</i> , <i>TTCGGTTGGT</i> (no match), <i>alpha4GnT</i> , <i>Hs.290723</i> , <i>AKT3</i> , <i>CCT3</i> , <i>HMG20A</i>
Downregulated	<i>Hs.216636</i> , <i>LOC116228</i> , <i>SH3MD2</i> , <i>NAB1</i> , <i>TTCCCCCAA</i> (no match), <i>DDX5</i> , <i>VMP1</i> , <i>LOC51123</i> , <i>LZK1</i> , <i>CGCAGATCAG</i> (no match), <i>IFRD2</i> , <i>Hs.284464</i> , <i>RPS4Y</i> , <i>RPS4Y2</i> , <i>UAP1</i> , <i>Hs.180804</i> , <i>CATTAAATTA</i> (no match), <i>IKBKAP</i> , <i>ARPC3</i> , <i>NAGA</i> , <i>UBE3A</i> , <i>TRAG3</i> , <i>PNN</i> , <i>CTAATTCTTT</i> (no match), <i>TCCATCGTCC</i> (no match)
The 20 most upregulated and downregulated tags and genes in metastatic tumor in comparison with primary tumor of gastric carcinoma <sup>a</sup>	
Upregulated	<i>SCAND1</i> , <i>RGS5</i> , <i>S100A11</i> , <i>RNPC2</i> , <i>APOE</i> , <i>FLJ10815</i> , <i>RNASE1</i> , <i>H3F3B</i> , <i>P24B</i> , <i>LOC151103</i> , <i>CLDN3</i> , <i>MRPL14</i> , <i>PRex1</i> , <i>TCCCCTATTA</i> (no match), <i>Hs.105379</i> , <i>ATP5G1</i> , <i>NPD007</i> , <i>MGC3180</i> , <i>WDR11</i> , <i>ARPC1B</i> , <i>ABTB2</i> , <i>DNAJB1</i> , <i>HMG2N</i> , <i>KIAA1393</i> , <i>RAP1B</i> , <i>FLJ12150</i> , <i>STUB1</i>
Downregulated	<i>ERdj5</i> , <i>RPL27A</i> , <i>DHRS3</i> , <i>E2IG5</i> , <i>USP7</i> , <i>CTSL</i> , <i>KRTHB1</i> , <i>KRTHB3</i> , <i>TGCACTACCC</i> (no match), <i>ALG12</i> , <i>S100A9</i> , <i>CTAGCTTTTA</i> (no match), <i>ELOVL5</i> , <i>LOC375463</i> , <i>GGGGGAGTTT</i> (no match), <i>ACTGCCCTCA</i> (no match), <i>SPC18</i> , <i>CTNND1</i> , <i>CYP20A1</i> , <i>FLJ11151</i> , <i>RPS17</i> , <i>ZYX</i> , <i>RPS16</i> , <i>GCTTTCTCAC</i> (no match), <i>BCL2L2</i>

Symbol of gene is described; UniGene ID is described if symbol is not present

No match, tag sequence is not matched to known gene

<sup>a</sup>Because some genes share the same SAGE tag, gene numbers are more than 20

metastatic tumor of gastric carcinoma included *SCAN D1*, *RGS5*, *S100A11*, *RNPC2*, and *APOE* [58]. *APOE* (apolipoprotein E) expression is associated with T grade, N grade, and advanced stage.

SAGE is also useful to isolate novel biomarkers of gastric carcinoma. The ideal biomarker should be overexpressed in a majority of gastric carcinoma and expressed on the cell surface or secreted to facilitate its detection. Moreover, if the function of the gene product is involved in the neoplastic process, the gene is not just a biomarker but can be a therapeutic target. One example is *REGIV* (regenerating gene type IV), which is identified by comparing the expressed tags of poorly differentiated nonsolid type (scirrhous-type) gastric carcinoma with those of normal gastric epithelia [58,60]. About half of gastric carcinomas overexpress *REGIV* mRNA regardless of tumor stage and histological differentiation. In vitro studies using *RegIV*-transfected cells revealed that RegIV is secreted by carcinoma cells and that RegIV inhibits apoptosis, suggesting that RegIV may serve as a novel biomarker and therapeutic target for gastric carcinoma. Other examples include *GW112* and *MIA*, both of which encode secreting proteins [61,62]. *GW112* demonstrates strong antiapoptotic effects in cancer cells treated with stress exposures and forced expression of *GW112* leads to more rapid tumor formation, indicating that *GW112* plays an important role in tumor cell survival and growth and should be a good therapeutic target [61].

### *Clinical Implication of Global Gene Expression Analysis*

A strategy to clinical applications of global analysis of gene expression such as diagnostics, treatment, and prevention is shown in Fig. 3. According to gene expression profiles among gastric carcinomas or with those in normal gastric tissue obtained by microarray study or SAGE, specifically upregulated or downregulated genes are identified. The expression of these genes is confirmed in a large number of cases by real-time RT-PCR and immunohistochemistry if antibodies are available. With the specific genes identified by SAGE, known genes participating in the development and progression of gastric carcinoma and known genetic markers for chemosensitivity, a custom-made cDNA microarray is prepared. If the specific gene encodes secretory protein, this may be detected in the blood and should be a novel biomarker of gastric carcinoma. For such molecules, DNA/RNA aptamer or antibody is produced to establish a measuring system such as enzyme-limited immunosorbent assay (ELISA) in blood sample. These methods can be applied for clinical diagnosis and cancer detection. Polymorphism of genes, highly altered in their expression in gastric carcinoma, may be candidates of novel risk factors, and this information will be used for cancer prevention. By functional analysis, the molecular mechanism of stomach carcinogenesis can be understood in more detail and the possibility whether the genes are novel therapeutic targets can be revealed. Combination of these testings not only can attain cancer detection but also can clarify the character of an individual tumor and person, which is directly connected with personalized medicine and cancer prevention.

## Conclusion

In the course of multistep carcinogenesis of the stomach, various alterations of oncogenes, tumor suppressor genes, DNA repair genes, growth factors/receptors, cell-cycle

regulators, and cell adhesion molecules are accumulated. Some of these changes occur commonly in both well-differentiated and poorly differentiated types and some differ depending on the histological types. Among various epigenetic alterations, modified gene expression through DNA methylation and chromatin remodeling by histone modification are the most important events. Genetic polymorphism is a crucial endogenous cause and fundamental factor of cancer risk. Using genomic science including novel techniques for global analysis of gene expression and bioinformatics, the individual character of each person and cancer can be dissected precisely, which is directly connected to personalized medicine and cancer prevention. Understanding of the diversity of gastric cancer must be critical in the era of genomic medicine at the clinical setting.

## References

1. Tahara E (1993) Molecular mechanism of stomach carcinogenesis. *J Cancer Res Clin Oncol* 119:265–272
2. Yasui W, Oue N, Kuniyasu H, et al (2001) Molecular diagnosis of gastric cancer: present and future. *Gastric Cancer* 4:113–121
3. Ohgaki H, Yasui W, Yokota J (2003) Genetic pathway to human cancer. In: Vainio H, Hietanen E (eds) *Handbook of experimental pharmacology. Mechanisms in carcinogenesis and cancer research*. Springer, Heidelberg, pp 25–39
4. Yokozaki H, Yasui W, Tahara E (2001) Genetic and epigenetic changes in stomach cancer. *Int Rev Cytol* 204:49–95
5. Yasui W, Oue N, Ono S, et al (2003) Histone acetylation and gastrointestinal carcinogenesis. *Ann NY Acad Sci* 983:220–231
6. Todaro GJ, Huebner RJ (1972) N.A.S. symposium: new evidence as the basis for increased efforts in cancer research. *Proc Natl Acad Sci U S A* 69:1009–1015
7. Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. *Proc Natl Acad Sci U S A* 68:820–823
8. Nakasato F, Sakamoto H, Mori M, et al (1984) Amplification of the c-myc oncogene in human stomach cancers. *Gann (Jpn J Cancer Res)* 75:737–742
9. Sakamoto H, Mori M, Taira M, et al (1986) Transforming gene from human stomach cancers and a noncancerous portion of stomach mucosa. *Proc Natl Acad Sci U S A* 83:3997–4001
10. Yasui W, Yokozaki H, Shimamoto F, et al (1999) Molecular-pathological diagnosis of gastrointestinal tissues and its contribution to cancer histopathology. *Pathol Int* 49:763–774
11. Kim NW, Piatyszek MA, Prowse KR, et al (1994) Specific association of human telomerase activity with immortal cells and cancer. *Science* 266:2011–2015
12. Yasui W, Tahara E, Tahara E, et al (1999) Immunohistochemical detection of human telomerase reverse transcriptase in normal and precancerous lesions of the stomach. *Jpn J Cancer Res* 90:589–595
13. Kondo T, Oue N, Mitani Y, et al (2005) Loss of heterozygosity and histone hypoacetylation of the PINX1 gene are associated with reduced expression in gastric carcinoma. *Oncogene* 24:157–164
14. Kondo T, Oue N, Yoshida K, et al (2004) Expression of POT1 is associated with tumor stage and telomere length in gastric carcinoma. *Cancer Res* 64:523–529
15. Fleisher AS, Esteller M, Wang S, et al (1999) Hypermethylation of the *hMLH1* promoter in human gastric cancers with microsatellite instability. *Cancer Res* 59:1090–1095
16. Takahashi Y, Cleary KR, Mai M, et al (1996) Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. *Clin Cancer Res* 2:1679–1684

17. Kitadai Y, Haruma K, Sumii K, et al (1998) Expression of IL-8 correlates with vascularity in human gastric carcinomas. *Am J Pathol* 152:93–100
18. Takahashi Y, Bucana CD, Akagi Y, et al (1998) Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer. *Clin Cancer Res* 4:429–434
19. Kitadai Y, Takahashi Y, Haruma K, et al (1999) Transfection of interleukin-8 increases angiogenesis and tumorigenesis of human gastric carcinoma cells in nude mice. *Br J Cancer* 81: 647–653
20. Kitadai Y, Haruma K, Mukaida N, et al (2000) Regulation of disease-progression genes in human gastric carcinoma cells by interleukin-8. *Clin. Cancer Res* 6:2735–2740
21. Kitadai Y, Sasaki A, Ito M, et al (2003) *Helicobacter pylori* infection influences expression of genes related to angiogenesis and invasion in human gastric carcinoma cells. *Biochem Biophys Res Commun* 311:809–814
22. Tatematsu M, Tsukamoto T, Inada K (2003) Stem cells and gastric cancer: role of gastric and intestinal mixed intestinal metaplasia. *Cancer Sci* 94:135–141
23. Ohmura K, Tamura G, Endoh Y, et al (2000) Microsatellite alterations in differentiated-type adenocarcinomas and precancerous lesions of the stomach with special reference to cellular phenotype. *Hum Pathol* 31:1031–1035
24. Yokozaki H, Shitara Y, Fujimoto J, et al (1999) Alterations of p73 preferentially occur in gastric adenocarcinomas with foveolar epithelial phenotype. *Int J Cancer* 83:192–196
25. Almeida R, Silva E, Santos-Silva F, et al (2003) Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas. *J Pathol* 199:36–40
26. Yamamoto H, Bai YQ, Yuasa Y (2003) Homeodomain protein CDX2 regulates goblet-specific MUC2 gene expression. *Biochem Biophys Res Commun* 300:813–818
27. Grotzinger C, Kneifel J, Patschan D, et al (2001) LI-cadherin: a marker of gastric metaplasia and neoplasia. *Gut* 49:73–81
28. Hippo Y, Taniguchi H, Tsutsumi S, et al (2002) Global gene expression analysis of gastric cancer by oligonucleotide microarrays. *Cancer Res* 62:233–240
29. Yasui W, Oue N, Ito R, et al (2004) Search for new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications. *Cancer Sci* 95:385–392
30. Hinoi T, Lucas PC, Kuick R, et al (2002) CDX2 regulates liver intestine-cadherin expression in normal and malignant colon epithelium and intestinal metaplasia. *Gastroenterology* 123: 1565–1577
31. Oshimo Y, Oue N, Mitani Y, et al (2004) Frequent loss of RUNX3 expression by promoter hypermethylation in gastric carcinoma. *Pathobiology* 71:137–143
32. Oue N, Shigeishi H, Kuniyasu H, et al (2001) Promoter methylation of MGMT is associated with protein loss in gastric carcinomas. *Int J Cancer* 93:805–809
33. Oue N, Matsumura S, Nakayama H, et al (2003) Expression of the TSP-1 gene and its association with promoter hypermethylation in gastric carcinomas. *Oncology* 64:423–429
34. Hamai Y, Oue N, Mitani Y, et al (2003) DNA methylation and histone acetylation status of HMTF gene are associated with reduced expression in gastric carcinoma. *Cancer Sci* 94:692–698
35. Oshimo Y, Oue N, Mitani Y, et al (2004) Frequent epigenetic inactivation of RIZ1 by promoter hypermethylation in human gastric carcinoma. *Int J Cancer* 110:212–218
36. Satoh A, Toyota M, Itoh F, et al (2003) Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. *Cancer Res* 63:8606–8613
37. Toyota M, Ahuja N, Suzuki H, et al (1999) Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. *Cancer Res* 59:5438–5442
38. Kaneda A, Kaminishi M, Yanagihara K, et al (2002) Identification of silencing of nine genes in human gastric cancers. *Cancer Res* 62:6645–6650
39. Oue N, Motoshita J, Yokozaki H, et al (2002) Distinct promoter hypermethylation of p16ink4a, CDH1, and RAR-beta in intestinal, diffuse-adherent, and diffuse-scattered type gastric carcinoma. *J Pathol* 198:55–59
40. Oue N, Oshimo Y, Mitani Y, et al (2003) DNA methylation of multiple genes in gastric carcinoma: association with histological type and CpG island methylator phenotype. *Cancer Sci* 94:901–905

41. Kang GH, Shim Y-H, Jung H-Y, et al (2001) CpG island methylation in premalignant stages of gastric carcinoma. *Cancer Res* 61:2847–2851
42. Rhee I, Bachman KE, Park BH, et al (2002) DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. *Nature (Lond)* 416:552–556
43. Robert M-F, Morin S, Beaulieu N, et al (2003) DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. *Nat Genet* 33:61–65
44. Kouzarides T (1999) Histone acetylases and deacetylases in cell proliferation. *Curr Opin Genet Dev* 9:40–48
45. Kouzarides T (2002) Histone methylation in transcriptional control. *Curr Opin Genet Dev* 12:198–209
46. Gonzalez CA, Sala N, Capella G (2002) Genetic susceptibility and gastric cancer risk. *Int J Cancer* 100:249–260
47. Wu M-S, Huang S-P, Chang Y-T, et al (2002) Association of the –160 C → A promoter polymorphism of the *E-cadherin* gene with gastric carcinoma risk. *Cancer (Phila)* 94:1443–1448
48. Pharoah PDP, Oliveira C, Machado JC, et al (2002) *CDH1* c-160a promoter polymorphism is not associated with risk of stomach cancer. *Int J Cancer* 101:196–197
49. Watters JW, McLeod HL (2003) Cancer pharmacogenomics: current and future applications. *Biochim Biophys Acta* 1603:99–111
50. El-Rifai W, Frierson HF Jr, Harper JC, et al (2001) Expression profiling of gastric adenocarcinoma using cDNA array. *Int J Cancer* 92:832–838
51. Hasegawa S, Furukawa Y, Li M, et al (2002) Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23 040 genes. *Cancer Res* 62:7012–7017
52. Inoue H, Matsuyama A, Mimori K, et al (2002) Prognostic score of gastric cancer determined by cDNA microarray. *Clin Cancer Res* 8:3475–3479
53. Zembutsu H, Ohnishi Y, Tsunoda T, et al (2002) Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anti-cancer drugs. *Cancer Res* 62:518–527
54. Velculescu VE, Zhang L, Vogelstein B, et al (1995) Serial analysis of gene expression. *Science* 270:484–487
55. El-Rafai W, Moskaluk CA, Abdrabbo MK, et al (2002) Gastric cancers overexpress S100A calcium-binding proteins. *Cancer Res* 62:6823–6826
56. Oien KA, Vass JK, Downie I, et al (2003) Profiling, comparison and validation of gene expression in gastric carcinoma and normal stomach. *Oncogene* 22:4287–4300
57. Lee J-Y, Eom E-M, Kim D-S, et al (2003) Analysis of gene expression profiles of gastric normal and cancer tissues by SAGE. *Genomics* 82:78–85
58. Oue N, Hamai Y, Mitani Y, et al (2004) Gene expression profile of gastric carcinoma; identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression. *Cancer Res* 64:2397–2405
59. Hicks GG, Singh N, Nashabi A, et al (2000) *Fus* deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability and perinatal death. *Nat Genet* 24:175–179
60. Hartupee JC, Zhang H, Bonaldo MF, et al (2001) Isolation and characterization of a cDNA encoding a novel member of the human generating protein family. *Biochim Biophys Acta* 1518:287–293
61. Zhang X, Huang Q, Yang Z, et al (2004) GW112, a novel antiapoptotic protein that promotes tumor growth. *Cancer Res* 64:2474–2481
62. Krupnik VE, Sharp JD, Jiang C, et al (1999) Functional and structural diversity of the human Dickkopf gene family. *Gene (Amst)* 238:301–313

*Color Plates* to appear on the following pages.




FIG. 1. Multiple genetic and epigenetic alterations during stomach carcinogenesis. Words printed in dark blue represent genetic alterations and those in green represent epigenetic alterations




FIG. 2. Schematic illustration of cancer cells and macrophages in angiogenesis. *MCP-1*, monocyte chemoattractant protein-1; *IL*, interleukin; *TNF-α*, tumor necrosis factor-alpha; *VEGF*, vascular endothelial growth factor; *EGFR*, epidermal growth factor receptor; *PD-ECGF*, platelet-derived endothelial cell growth factor; *IL-8R*, IL-8 receptor




FIG. 3. Strategy to search for novel genes of gastric cancer through gene expression profiles and its clinical implication. *SAGE*, serial analysis of gene expression; *SNP*, single nucleotide polymorphism




---

# 慢性肝炎治療薬の 選び方と使い方

---

広島大学大学院教授  
(財)放射線影響研究所  
広島大学病院

茶山一彰 編著  
大石和佳 共著  
今村道雄



---

南江堂

# 目次

序章 B 型, C 型慢性肝炎の治療の考え方	1
1. B 型慢性肝炎	5
A. B 型肝炎ウイルス	5
① B 型肝炎ウイルスの構造	5
② B 型肝炎ウイルスの蛋白と機能	7
③ ウイルスの genotype	9
B. B 型慢性肝炎の自然経過	11
① B 型慢性肝炎の典型例	12
② B 型肝炎ウイルスの増殖メカニズム	14
③ 臨床的治癒と治療の到達目標	15
C. ステロイド離脱療法	16
① ステロイド離脱療法の考え方	16
② ステロイド離脱療法の適応	17
③ ステロイド離脱療法の典型的な経過	18
④ ステロイド離脱療法の禁忌	19
⑤ 非典型例の取り扱い	19
D. インターフェロンによる治療	21
① IFN による B 型肝炎の治療の考え方	21
② IFN $\alpha$ による治療	25
③ IFN $\beta$ による治療	26
④ IFN の副作用	28
E. lamivudine による治療	32
① lamivudine の構造と働き	33
② lamivudin 治療の対象と効果	34
③ 耐性株の診断と問題点	39
④ 耐性株に対する対策	40
⑤ 耐性株検出の高感度化と問題点	41
F. adefovir およびその他の核酸アナログ	44
① adefovir dipivoxil	44
② entecavir	47

③ その他の核酸アナログ	47
G. 肝底護療法	50
① 強力ネオミノファーゲン C (SNMC)	50
② ウルソデオキシコール酸 (UDCA)	52
③ 小柴胡湯	53
2. C 型慢性肝炎	55
A. C 型肝炎ウイルス	55
① C 型肝炎ウイルスの構造	55
② C 型肝炎ウイルスの蛋白と機能	56
③ C 型肝炎ウイルスの増殖メカニズム	57
④ サブタイプとウイルス量	58
B. C 型慢性肝炎の自然経過と治療	62
① C 型慢性肝炎の典型例	62
② C 型肝炎発症のメカニズム	63
③ 治療の考え方	64
C. ガイドラインの解説	66
① 初回治療のガイドライン	66
② 再治療のガイドライン	67
③ genotype 1 b, 高ウイルス量に対する IFN 単独長期療法の ガイドライン	68
④ IFN 無効例, 非適応例に対する治療のガイドライン	69
D. インターフェロン単独による治療	70
① HCV の IFN 感受性	70
② C 型慢性肝炎易治療例の典型例と治療の考え方	72
③ C 型慢性肝炎難治療例の典型例と治療の考え方	74
④ IFN 療法による長期予後	75
E. ribavirin とインターフェロンの併用療法	79
① ribavirin の作用機序	79
② ribavirin と IFN の併用療法の治療効果	81
③ ribavirin の副作用, 使用上の注意	87
F. コンセンサスインターフェロン	90
① Con-IFN の特徴	90
② Con-IFN の治療のターゲット	91
③ 将来の ribavirin 併用投与の可能性	96

G. PEG インターフェロン	98
① PEG-IFN の構造と特性	98
② PEG-IFN 単独投与による C 型慢性肝炎の治療	100
③ ribavirin 併用投与の効果と限界	103
④ PEG-IFN の副作用	106
H. 肝庇護療法	107
① 強力ネオミノファーゲン C (SNMC)	107
② ウルソデオキシコール酸 (UDCA)	109
③ 小柴胡湯	110
I. 瀉血	113
① 瀉血療法の背景と原理	113
② 瀉血療法の実際	114
③ 瀉血療法後の維持療法	116
J. その他の治療	118
① 現治療に対する付加療法	118
② 小分子標的薬とウイルス酵素阻害薬	120
③ その他	123
薬剤一覧	125
索引	131